Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
22 Feb 2021 7:00 am
RNS
Voluntary withdrawal Imfinzi US bladder indication
17 Feb 2021 7:00 am
RNS
Lynparza: IDMC recommend early analysis of OlympiA
16 Feb 2021 11:15 am
RNS
Filing of Form 20-F with SEC
15 Feb 2021 3:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Annual Financial Report
11 Feb 2021 7:01 am
RNS
AstraZeneca Non-Executive Board changes
  7:00 am
RNS
AZN: full-year 2020 results
10 Feb 2021 7:00 am
RNS
Divestment of Crestor in Europe completed
05 Feb 2021 7:00 am
RNS
Update on KESTREL Phase III trial for Imfinzi
04 Feb 2021 7:00 am
RNS
Forxiga approved in China for heart failure
01 Feb 2021 3:00 pm
RNS
Total Voting Rights
  12:15 pm
RNS
AstraZeneca agrees to divest Viela shareholding
  7:00 am
RNS
COVID-19 vaccine authorised for use by the EU
29 Jan 2021 3:16 pm
RNS
COVID-19 vaccine receives positive opinion in EU
26 Jan 2021 3:00 pm
RNS
Block listing application
  7:00 am
RNS
Symbicort approved in China for mild asthma
25 Jan 2021 7:05 am
RNS
Calquence approved in Japan for CLL
  7:00 am
RNS
Calquence met primary endpoint against ibrutinib
20 Jan 2021 7:00 am
RNS
Enhertu approved in the EU for breast cancer
18 Jan 2021 7:00 am
RNS
Enhertu approved in the US for gastric cancer
15 Jan 2021 7:00 am
RNS
Imfinzi new dosing approved in EU
06 Jan 2021 7:00 am
RNS
Farxiga granted US Priority Review for CKD
04 Jan 2021 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Atacand divestment in over 70 countries completed
30 Dec 2020 7:00 am
RNS
AstraZeneca's COVID-19 vaccine authorised in UK
29 Dec 2020 7:00 am
RNS
Lynparza approved in Japan for three cancers
21 Dec 2020 7:05 am
RNS
Tagrisso approved in the US for early lung cancer
  7:00 am
RNS
Update on US regulatory review of roxadustat
17 Dec 2020 4:00 pm
RNS
Director/PDMR Shareholding
16 Dec 2020 6:15 pm
RNS
Director/PDMR Shareholding
15 Dec 2020 7:00 am
RNS
Imfinzi new dose receives positive EU CHMP opinion
14 Dec 2020 7:05 am
RNS
Trastuzumab deruxtecan positive CHMP
  7:00 am
RNS
Trixeo Aerosphere approved in the EU for COPD
  7:00 am
RNS
AstraZeneca to acquire Alexion Pharmaceuticals Inc
01 Dec 2020 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Crestor to be divested to Gr?nenthal in Europe
30 Nov 2020 7:00 am
RNS
Forxiga approved in Japan for heart failure
23 Nov 2020 7:00 am
RNS
AZD1222 vaccine effective against COVID-19
20 Nov 2020 7:00 am
RNS
Imfinzi new dosing approved in the US
10 Nov 2020 7:00 am
RNS
Tezepelumab Phase III trial met primary endpoint
09 Nov 2020 7:00 am
RNS
Calquence approved in the EU for CLL
06 Nov 2020 7:00 am
RNS
Brilinta approved in the US in stroke
05 Nov 2020 7:15 am
RNS
Lynparza approved in the EU for wider ovarian use
  7:10 am
RNS
Lynparza approved in the EU for prostate cancer
  7:05 am
RNS
Forxiga approved in the EU for heart failure
  7:00 am
RNS
AZN: Year-to-date and Q3 2020 results
02 Nov 2020 3:00 pm
RNS
Total Voting Rights
30 Oct 2020 7:00 am
RNS
Atacand to be divested in more than 70 countries
29 Oct 2020 7:00 am
RNS
Directorate Change
28 Oct 2020 7:03 am
RNS
Enhertu US Priority Review in gastric cancer
  7:00 am
RNS
Forxiga CV outcomes benefit approved in China
20 Oct 2020 7:00 am
RNS
Tagrisso adjuvant lung cancer US Priority Review
19 Oct 2020 7:00 am
RNS
Forxiga HF receives positive CHMP opinion
  7:00 am
RNS
Trixeo Aerosphere receives positive CHMP opinion
12 Oct 2020 7:00 am
RNS
COVID-19 antibodies advance and get US funding
02 Oct 2020 11:19 am
RNS
Holding(s) in Company
  7:00 am
RNS
Farxiga granted US BTD in chronic kidney disease
01 Oct 2020 3:00 pm
RNS
Total Voting Rights
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t